| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.3233/JAD-2006-9S316 |
| P698 | PubMed publication ID | 16914852 |
| P2093 | author name string | Manuel Buttini | |
| Dale Schenk | |||
| Dora Games | |||
| Peter Seubert | |||
| Dione Kobayashi | |||
| P433 | issue | 3 Suppl | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 133-149 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Mice as models: transgenic approaches and Alzheimer's disease | |
| P478 | volume | 9 |
| Q38368071 | A comparative study of five mouse models of Alzheimer's disease: cell cycle events reveal new insights into neurons at risk for death |
| Q35216697 | A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ. |
| Q37078850 | APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease. |
| Q33771171 | Accumulation of intraneuronal Abeta correlates with ApoE4 genotype |
| Q30357424 | Alzheimer 100--highlights in the history of Alzheimer research. |
| Q30535426 | Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation |
| Q37671455 | Alzheimer's disease and the amyloid-beta peptide |
| Q35687044 | Alzheimer's disease: pathological mechanisms and recent insights |
| Q37636545 | Alzheimer's disease: synaptic dysfunction and Abeta |
| Q35058977 | Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8). |
| Q36040886 | Amyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse model |
| Q41578684 | Amyloid β Enhances Typical Rodent Behavior While It Impairs Contextual Memory Consolidation |
| Q42241419 | Amyloid-beta dynamics correlate with neurological status in the injured human brain |
| Q33993315 | Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines |
| Q33292558 | Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life |
| Q37118083 | Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? |
| Q34903853 | Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease |
| Q34982179 | Combination therapy prevents amyloid-dependent and -independent structural changes |
| Q41979914 | Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice |
| Q46655961 | Decreased hippocampal cell proliferation correlates with increased expression of BMP4 in the APPswe/PS1DeltaE9 mouse model of Alzheimer's disease |
| Q35207688 | Fiber Tracts Anomalies in APPxPS1 Transgenic Mice Modeling Alzheimer's Disease |
| Q38659874 | Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology |
| Q38007991 | GPR18 in microglia: implications for the CNS and endocannabinoid system signalling |
| Q34157658 | Global analysis of S-nitrosylation sites in the wild type (APP) transgenic mouse brain-clues for synaptic pathology |
| Q24599108 | Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
| Q46798116 | Immunotherapy reduces vascular amyloid-beta in PDAPP mice. |
| Q33427621 | In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment |
| Q34669518 | Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? |
| Q37765478 | Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease |
| Q37215837 | Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease |
| Q37710380 | Microglia in neurodegenerative disease |
| Q34143614 | Neuron loss in transgenic mouse models of Alzheimer's disease |
| Q35993835 | Ocular manifestations of Alzheimer's disease in animal models. |
| Q24650014 | Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases |
| Q24671711 | Protein folding: then and now |
| Q37802279 | Selecting a Mouse Model of Alzheimer’s Disease |
| Q43516778 | Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. |
| Q33829008 | Targeting Abeta and tau in Alzheimer's disease, an early interim report |
| Q92403132 | Targeting Synaptic Plasticity in Experimental Models of Alzheimer's Disease |
| Q36742787 | The PPAR-gamma Agonist 15-Deoxy-Delta-Prostaglandin J(2) Attenuates Microglial Production of IL-12 Family Cytokines: Potential Relevance to Alzheimer's Disease |
| Q36646116 | The blockage of the Nogo/NgR signal pathway in microglia alleviates the formation of Aβ plaques and tau phosphorylation in APP/PS1 transgenic mice |
| Q82647986 | Transgenic mouse models of Alzheimer's disease |
| Q26824702 | Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales |
| Q38171298 | Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle |
| Q53395770 | [Alzheimer's disease. Molecular pathology, animal models, and current treatment]. |
Search more.